1Law M,Palomaki G,Alfirevic Z,et al.The prevention of neonatal group B streptococcal disease:a report by a working group of the Medical Screening Society[J].J Med Screen,2005,12(2):60-68.
3Wessels MR,Paoletti LC,Guttormsen HK,et al.Structural properties of Group B streptococcal Type Ⅲ polysaccharide conjugate vaccines that influence immunogenicity and efficacy[J].Infect Immun,1998,66(5):2186-2192.
4Baker CJ,Rench MA,Mclnnes P.Immunization of pregnant women with group B streptococcal Type Ⅲ capsular polysaccharide-Tetanus toxoid conjugate vaccine[J].Vaccine,2003,21 (24):3468-3472.
5Palazzi DL,Rench MA,Edwards MS,et al.Use of Type V group B streptococcal conjugate vaccine in adults 65-85 years old[J].J Infect Dis,2004,190(3):558-564.
6Heath PT,Feldman RG.Vaccination against Group B streptococcus[J].Expert Rev Vaccines,2005,4(2):207-218.
7Baker CJ,Rench MA,Fernandez M,et al.Safety and Immunogenicity of a Bivalent Group B Streptococcal Conjugate Vaccine for Serotypes Ⅱ and Ⅲ[J].J Infect Dis,2003,188(1):66-73.
8Cheng Q,Debols,Lam H,et al.Immunization with C5a peptidase or peptidase-Type II polysaccharide conjugate vaccines enhances clearance of Group B streptococci from lungs of infected mice[J].Infect Immun,2002,70(11):6409-6415.
9Bemer R,Bender A,Rensing C,et al.Low prevalence of the immunoglobulin-Abirding beta antgen of the C protein among Streptococcus agalactiae isolates causing neonatal sepsis[J].Eur J Clin Microbiol Infect Dis,1999,18(8):545-550.
10Maeland JA,Bevanger L,Lyng RV.Antigenic Determinants of Alpha-Like Proteins of Streptococcus agalactiae[J].Clin Diagn Lab Immunol,2004,11(6):1035-1039.
9Heath PT,Feldman RG.Vaccination against group B streptococcus[J].Expert Rev Vaccines,2005,4(2):207-218.
10Cheng Q,Carlson B,Pillai S,et al.Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci[J].Infect Immun,2001,69(4):2302-2308.
